You are here: Industry Insights > BPD

News List

Survey Highlights Difficulties of Living With Bipolar Disorder drugs.com
January 13, 2022
Living with and managing bipolar I disorder (BD-I) remains a profoundly challenging experience, according to the results of a survey released by the pharmaceutical..
Stem cell transplantation may be able to prevent major cause of death in preterm infants europeanpharmaceuticalreview
April 22, 2021
Transplanting stem cells directly into the trachea of preterm infants with bronchopulmonary dysplasia was found to be safe and of some benefit in the most vulnerable group.
Airway Announces IND Acceptance of AT-100 for Preterm Infants at Risk for BPD americanpharmaceuticalreview
April 02, 2021
Airway Therapeutics announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to develop AT-100 (rhSP-D) as a preventive treatment for the serious respiratory disease BPD in very preterm babies.
Airway Therapeutics Announces FDA Acceptance of IND for AT-100 in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD) prnasia
March 26, 2021
Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, today announced the U.S. Food and Drug Administration ...
University of Oxford, Sound Pharmaceuticals Complete Phase 2 Bipolar Disorder Study americanpharmaceuticalreview
May 11, 2020
The University of Oxford and Sound Pharmaceuticals (SPI) announced the successful completion of a Phase 2a study testing SPI-1005 as a new treatment for bipolar disorder (BPD).